Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
about
Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extractThe neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulationGlutamate and neurotrophic factors in neuronal plasticity and diseaseNeuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseDiagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarraysmGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in RatsNew therapeutic targets for mood disordersmGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotionBeyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats.Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.Activation of amygdalar metabotropic glutamate receptors modulates anxiety, and risk assessment behaviors in ovariectomized estradiol-treated female rats.Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5).Novel therapeutic drugs for neuropsychiatric disordersFenobam promoted the neuroprotective effect of PEP-1-FK506BP following oxidative stress by increasing its transduction efficiency.Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat hippocampus.On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.Aqueous and Ethanolic Valeriana officinalis Extracts Change the Binding of Ligands to Glutamate ReceptorsTranscriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonists MPEP and MTEPSelective Interactions of Valeriana officinalis Extracts and Valerenic Acid with [H]Glutamate Binding to Rat Synaptic MembranesPost-traumatic stress disorder: emerging concepts of pharmacotherapy.Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep.Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration.Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice.Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.Amygdalar activation of group I metabotropic glutamate receptors produces anti- and pro-conflict effects depending upon animal sex in a sexually dimorphic conditioned conflict-based anxiety model.REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effectsQuantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in MalesTargeting the glutamatergic system to develop novel, improved therapeutics for mood disordersPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsMetabotropic glutamate receptor ligands as potential therapeutics for addictionCharacterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688Emerging drugs for major depressive disorder.Glutamate receptors as therapeutic targets for Parkinson's disease.Metabotropic glutamate receptor subtype 5 antagonism in learning and memory.Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.
P2860
Q21132322-101A7308-349F-40A0-803B-0A9A022A81E4Q24613593-4028BC69-FFB1-4181-B373-63B4D06EC917Q24653626-3E8FDCD3-EFB4-4BAC-BF61-9C38EA1392A3Q26995351-0A706163-51F9-476F-A7F8-1A4626736053Q27496622-191D4D14-0224-4B49-9C18-443A10E9EB29Q28551598-BB30BE28-E90F-48EF-BADE-1165A8ECCBA1Q28743068-ABA1FE7F-2097-4F1A-A4A9-78E81D543EA3Q30450936-5EC80D6B-82FC-4D57-93F7-7A53E415FC97Q30473410-43F933E4-B961-4EFA-92B3-7553293C5E82Q33334413-7076A277-3850-4B65-AB4B-F14C39190913Q33678656-92A170AD-1116-4584-A7D3-137B8E96D96DQ33709219-7C259B06-30E4-4ED9-BE2F-064B4E9E21CEQ33769874-E8B762AC-1C07-4624-A095-2354D163F37EQ34018299-EF28664F-91C2-4694-A7E5-D2818BFB79CBQ34049298-80564F7E-7B94-4D8C-9EBA-708FFC989D54Q34054096-3F189D41-FC64-43A4-BCF9-E749B04EB073Q34130874-61B023F9-D473-4B8E-A541-57ADB6888CFBQ34382619-D970245E-0CE4-4370-853E-E04D7C3355B7Q34762404-5FE03E1E-E7C0-4D1E-B653-7F546EFE681CQ34974640-59EBBF68-D6E8-4C55-B71C-5572F7D9423AQ34981801-DEA379D6-8F59-4650-959F-24273C05FF80Q35085729-C6BA699E-F3DB-4D9E-A77D-7194203568E3Q35661119-3C414201-36D3-4891-BD7B-FB12C730DD62Q35888578-0DCBA5C9-313B-4024-B3D2-E3A9A7E75373Q36233639-26FB52D1-339F-468C-A56D-95FE14E3AA88Q36662527-BCB1B444-2390-42A1-9A33-A161473B468BQ36733346-E9FB9754-5FB0-41EF-8DF3-50441BA18E50Q36755346-63409EC6-F4F1-492C-8AA9-E21F028FDC3FQ36808854-0BDDFEEF-D122-4854-94C1-9A1A6804DE04Q36821018-6058F7F6-47D7-4995-A808-48700622472AQ36903829-D135C785-A4C7-4989-803A-BF3CFE15B16EQ37024830-DF3C4056-10EA-4522-B8DE-03F889F86F17Q37143117-13C647CD-9C3B-481F-9906-5C2ED22CAE33Q37183072-85968DA7-CFF9-4385-8871-CBE7D0CCD3D5Q37280041-CDD21F64-C023-4EC4-8D57-0E01F6929E14Q37347468-0BA451FD-E010-414C-9744-92B7C918FA00Q37564562-DA3003C8-DE33-4996-97B8-BB304BEF3373Q37585401-8E86EC14-1941-4B82-A1BA-5D045323F7A5Q37723772-A398F673-6990-4455-9750-EC10D3FB3803Q37773480-DBC80026-E1E4-4C44-9CCA-C44128052E74
P2860
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@ast
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@en
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@nl
type
label
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@ast
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@en
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@nl
prefLabel
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@ast
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@en
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@nl
P1476
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
@en
P304
P356
10.1016/J.PHARMTHERA.2007.04.007
P407
P577
2007-07-01T00:00:00Z